First-in-human trial of an optimised lentiviral vector for cystic fibrosis gene therapy

A single dose of a genetically modified virus, delivered as a fine mist into the lungs, is about to be tested in people for the first time as a treatment for cystic fibrosis. Cystic fibrosis is caused by a faulty gene that makes lung mucus thick and sticky, trapping bacteria and slowly destroying the lungs. Existing drugs called modulators help some patients but do not fix the root genetic problem, and many people cannot take them. This trial tests vGM058, a lentiviral vector engineered to carry a correct copy of the CFTR gene directly into the cells lining the airways. The virus is based on a simian immunodeficiency virus backbone, chosen for its ability to infect non-dividing cells, and has been pseudotyped to latch onto airway cells efficiently. The team has already completed extensive preclinical work and is now moving to manufacture the vector under clinical-grade conditions, run required safety studies in mice, and then launch a phase 1 trial in humans. If the vector proves safe and delivers the gene effectively, it could offer a one-time, inhalable genetic correction for cystic fibrosis—something no current therapy provides. This is not a cure yet, but it is the first step toward a treatment that works regardless of a patient’s specific mutation.